MEKICS CO., Ltd
Financials
Valuation Metrics
MEKICS CO., Ltd's Market Cap is ₩250B. At end of 2025 it was ₩303B. Ranked #2181 of 2,436 in KR market (top 90%), #1413 of 1,649 on KOSDAQ (top 86%), #90 of 96 in Health Care Equipment & Services (top 94%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 25.02B KRW | KR#2,181/2,436 Sec#90/96 |
| Revenue | 12.26B KRW | KR#2,259/2,436 Sec#78/96 |
| Net Income | -904.3M KRW | KR—/2,436 Sec—/96 |
| Total Assets | 57.31B KRW | KR#2,117/2,436 Sec#70/96 |
| Net Assets | 37.21B KRW | KR#2,073/2,436 Sec#75/96 |
| Employees | 106 | KR#1,589/2,436 Sec#54/96 |
| Value | ||
| P/B | 0.67x | KR#1,109/2,436 Sec#22/96 |
| P/S | 2.04x | KR#1,829/2,436 Sec#49/96 |
| FCF Yield | -10.23% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -2.43% | KR#1,638/2,436 Sec#55/96 |
| ROA | -1.58% | KR#1,660/2,436 Sec#54/96 |
| Op. Margin | -11.07% | KR#2,006/2,436 Sec#65/96 |
| Revenue Growth | 33.35% | KR#436/2,436 Sec#18/96 |
| Financial Health | ||
| Debt Ratio | 154.03% | KR#1,242/2,436 Sec#65/96 |
| Total Debt | 15.49B KRW | KR#1,463/2,436 Sec#45/96 |
| FCF | -2.56B KRW | KR#1,372/2,436 Sec#44/96 |
| Cash | 4.24B KRW | KR#2,057/2,436 Sec#74/96 |
| Current Ratio | 1.27x | KR#1,499/2,436 Sec#74/96 |
| Dividend | ||
| Div. Yield | 1.89% | KR#915/2,436 Sec#22/96 |
| Performance | ||
| 1Y Return | -26.46% | KR#1,478/2,436 Sec#46/96 |
| 1M Return | -19.06% | KR#2,165/2,436 Sec#84/96 |
| From 52W High | -61.02% | KR#1,760/2,436 Sec#64/96 |
| 1Y MDD | -56.45% | KR#1,224/2,436 Sec#43/96 |
| Trading | ||
| Volume | 52,850 shares | KR#1,299/2,436 Sec#59/96 |
| Foreign Own. | 5.50% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -54 KRW | KR—/2,436 Sec—/96 |
| BPS | 2,396 KRW | KR#1,938/2,436 Sec#62/96 |
Company Info
Mecics, established in 1998 and listed on KOSDAQ in 2015, designs, manufactures, and sells medical devices such as artificial respirators, respiratory therapy devices, and patient monitoring devices for emergency rooms and intensive care units. The company developed Korea's first artificial respirator, securing international competitiveness. It leads the global market with world-class high-flow respiratory therapy technology and is expanding sales following US FDA approval and Japan PMDA registration. Mecics was established in 1998 and is headquartered in Paju, Gyeonggi-do.